Tweet
Vaccine. 2017 Feb 3. pii: S0264-410X(17)30088-9. doi: 10.1016/j.vaccine.2017.01.039. [Epub ahead of print]
Microarray profile of the humoral immune response to influenza vaccination in breast cancer patients treated with chemotherapy.
Wumkes ML1, van der Velden AM2, de Bruin E3, Meerveld-Eggink A4, Koopmans MP5, Rimmelzwaan GF6, Rijkers GT7, Biesma DH8.
Author information
Abstract
BACKGROUND:
Patients treated with chemotherapy have an impaired response to influenza virus vaccination compared to healthy controls. Little is known about the broadness of the antibody response in these patients.
METHODS:
Breast cancer patients on FEC (5-fluorouracil, epirubicin and cyclophosphamide) chemotherapy regimens were vaccinated with influenza virus vaccine. Sera were obtained before and three weeks after vaccination. In addition to the determination of virus-specific antibody titres by hemagglutination inhibition assay, the broadness of the response was assessed by the use of a protein microarray and baseline titres were compared with an age-matched reference group.
RESULTS:
We included 38 breast cancer patients and found a wide variety in serum antibody response after vaccination. Patients with a history of influenza vaccination had higher pre-vaccination titres, which were comparable to the reference group. Increasing number of cycles of chemotherapy did not have a negative effect on influenza array antibody levels, nor on the HI antibody response.
CONCLUSIONS:
Overall there was a broad serum antibody response to the influenza virus vaccine in patients treated with chemotherapy for breast cancer.
Copyright ? 2017. Published by Elsevier Ltd.
KEYWORDS:
Antigen microarray; Breast cancer; Chemotherapy; Influenza vaccination; Profiling immune response
PMID: 28169075 DOI: 10.1016/j.vaccine.2017.01.039
[PubMed - as supplied by publisher]
Microarray profile of the humoral immune response to influenza vaccination in breast cancer patients treated with chemotherapy.
Wumkes ML1, van der Velden AM2, de Bruin E3, Meerveld-Eggink A4, Koopmans MP5, Rimmelzwaan GF6, Rijkers GT7, Biesma DH8.
Author information
Abstract
BACKGROUND:
Patients treated with chemotherapy have an impaired response to influenza virus vaccination compared to healthy controls. Little is known about the broadness of the antibody response in these patients.
METHODS:
Breast cancer patients on FEC (5-fluorouracil, epirubicin and cyclophosphamide) chemotherapy regimens were vaccinated with influenza virus vaccine. Sera were obtained before and three weeks after vaccination. In addition to the determination of virus-specific antibody titres by hemagglutination inhibition assay, the broadness of the response was assessed by the use of a protein microarray and baseline titres were compared with an age-matched reference group.
RESULTS:
We included 38 breast cancer patients and found a wide variety in serum antibody response after vaccination. Patients with a history of influenza vaccination had higher pre-vaccination titres, which were comparable to the reference group. Increasing number of cycles of chemotherapy did not have a negative effect on influenza array antibody levels, nor on the HI antibody response.
CONCLUSIONS:
Overall there was a broad serum antibody response to the influenza virus vaccine in patients treated with chemotherapy for breast cancer.
Copyright ? 2017. Published by Elsevier Ltd.
KEYWORDS:
Antigen microarray; Breast cancer; Chemotherapy; Influenza vaccination; Profiling immune response
PMID: 28169075 DOI: 10.1016/j.vaccine.2017.01.039
[PubMed - as supplied by publisher]